Nirvana Life Sciences Inc · CSE:NIRV.X
Nirvana Life Sciences — Investor Presentation (December 2021)
26 slides from Nirvana Life Sciences's investor presentation, December 2021
Slide 1: Nirvana Life Sciences
NIRVANA LIFE SCIENCES Nirvana Life Sciences focused on developing medical products and regiments that address addiction. ~
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain information set forth in this presentation contains “forward- These statements are not guarantees of future performance and looking information”, including “future-oriented financial information” undue reliance should not be placed on them. Such forward-looking and
Slide 3: Situation
Situation Addiction to Opioids has become a global crisis. For many years, the pharmaceutical Industry has promoted the use of highly addictive pain medications to millions of patients. While these medications have been effective for pain relief, the highly addictive nature of the medications has cr
Slide 4: Cost of Opioid Crisis in America
Cost of Opioid Crisis in America The Council of Economic Advisors estimate the cost to the US economy at more than $500 billion annually. The impact can also be measured financially, with massive health care and insurance costs as well as the significant costs of law enforcement. This equates to alm
Slide 5: Our Mission
Our Mission Nirvana Life Sciences has been founded with a simple objective of developing non-addictive pain management products that can provide healthier outcomes for patients who live with chronic pain. We believe that using naturally sourced psychedelics in novel formulations holds the promise of
Slide 6: Three Keys to Success
Three Keys to Success 1. Formulation ▪ Acquired the IP behind these novel formulations 2. Extraction and Purification ▪ Acquired a license for the extraction technology ▪ Developing a proprietary process for purification of the materials 3. Scaleability ▪ Developing a scalable process for producing
Slide 7: Initial Products
Initial Products The Company has selected two products for its first phase: • A one-per-day slow release gel cap that assists transition from opioids to non-addictive pain relief therapies. • A one-per-day slow release gel cap that delivers non-addictive pain relief. • Development of similar product
Slide 8: Formulation Technology
Formulation Technology • The Company’s research team has developed novel formulations for non-addictive psilocybin based pain relief products that can be delivered through industry standard delivery systems. • The Company has developed formulations based on psychedelics for aiding patients who are a
Slide 9: Extraction
Extraction The Company has acquired an exclusive license to a proprietary extraction technology. It has secured the equipment to extract the active ingredient.
Slide 10: Purification
Purification Company Researchers have developed a process for purification of Psilosybins. Starting with the Company’s licensed Extraction process, a scalable process for purification of these materials has been developed and tested. It is expected that this process will render a cost-effective supp
Slide 11: Psilocybin and Psilocin
Psilocybin and Psilocin Growing several genera and species of fungi (including rare and Using a fully synthetic route to yield psilocybin and psilocin from 4-hy- hybrid varieties) in high volume with a high standard of quality and droxytryptophan in large batch quantities. This synthetic psilocybin
Slide 12: Iboga and Ibogaine (Tabernanthe Iboga)
Iboga and Ibogaine (Tabernanthe Iboga) Ibogaine is a naturally occurring alkaloid that has been reported to We are currently in the process of developing a cost effective batch decrease various adverse phenotypes associated with exposure to scale synthesis of noribogaine and its 13-hydroxy variant.
Slide 13: Dr. Sazzad Hossan
Dr. Sazzad Hossan Chief Scientific Officer He is the former Chief Scientific Officer of InMed Pharmaceuticals Inc., a leading public Canadian bio-pharmaceutical company. Previously he worked as Senior Scientist at Biotechnology Research Institute of National Research Council Canada. Working with the
Slide 14: Dr. Massimo Nabissi
Dr. Massimo Nabissi Dr Massimo Nabissi is Associate Professor at the University of Camerino in Italy, He is an Investigator in molecular and cellular biology studies in human cancers: glioblastoma, multiple myeloma, bladder and prostate. Teacher in General Pathology in School of Pharmacy and School
Slide 15: Dr. Robert Oberlender, PHD
Dr. Robert Oberlender, PHD Scientific Advisory Board Member Throughout his academic and professional careers, Dr. Oberlender Dr. Oberlender began his academic studies at Temple University in his has coauthored numerous scientific research articles and books home town of Philadelphia. He worked as a
Slide 16: Robert August IV, MSc
Robert August IV, MSc Robert August is an academically trained medicinal chemist with While forming BCRG, Robert was given unlimited access to the D.E. a focus on ergolines, phenethylamines and tryptamines. Robert Nichols Archive at Purdue University and the vast array of synthesis began his academi
Slide 17: Dr. Naseem Gaur and Dr. Bragesh Barse
Dr. Naseem Gaur and Dr. Bragesh Barse Dr. Gaur and Dr. Barse of the International Centre for Genetic Engineering and Biotechnology of New Dehli, India will undertake a research project on a novel process developed by the Company’s CSO to assess the ability to produce psilocybin materials at scale. T
Slide 18: Dr. Alasdair Barr, PHD
Dr. Alasdair Barr, PHD Dr. Barr is a Professor at the University of British Columbia with a focus on mental health and addictions research, using multidisciplinary and translational approach that spans from laboratory to clinic. Dr. Barr maintains active programs in both clinical and preclinical res
Slide 19: Sheldon Inwentash, B.Comm., CA., CPA., LL.D.
Sheldon Inwentash, B.Comm., CA., CPA., LL.D. Mr. Inwentash is the Founder, Chairman and CEO of ThreeD Capital Inc.. Mr. Inwentash has more than 30 years of investing experience. He co-founded Visible Genetics, the first commercial pharmacogenomics company, in 1994 and exited in 2001 to Bayer. Throug
Slide 20: Jackson Inwentash, CFA.
Jackson Inwentash, CFA. Mr. Inwentash is a director and VP Investments at ThreeD, where he focuses on identifying, researching, and meeting with early stage companies in various disruptive industries to invest into. Previously, he worked in investment banking for Gravitas Securities Inc. where he co
Slide 21: Pre-Clinical Trails
Pre-Clinical Trails • Clinical Studies will be led by Dr. Massimo Nabissi of the University of Camerino (Italy) with the support of Dr Sazzad Hossain. Dr. Nabissi has received government permission to work with these compounds. • Nirvana will be commencing preclinical trials into the efficacy of the
Slide 22: The Nirvana Advantage
The Nirvana Advantage 1. Delivery Nirvana’s proprietary delivery system formulations offer superior bioavailability and simple dose management. 2. Extraction Proprietary extraction technology 3. Market Approach Product focused approach shows a clear pathway to market 4. Quality Control Parallel deve
Slide 23: 2021 Budget
2021 Budget Reseatch and Development $1,050,000 Laboratory $920,000 IP Legal $295,000 G&A $235,000
Slide 24: Comparables
Comparables Mindmed $.94 $263 Million Compass Pathways $43.98 $1.5 Billion Numinus Wellness $0.28 $27 Million Nirvana Life Sciences $0.25/PPClosed $12.4 Million
Slide 25: Cap Table
Cap Table Founders 12,597,000 Inellectual Property Round 37,000,000 Private Placement $1.00 10,000,000 / 25,000,000
Slide 26: Contact
Contact Randy Rosiek / Founder randy@nirvanalifesciences.com Nirvana Life Sciences 6th Floor. 905 West Pender St. Vancouver BC V6C1L6
Nirvana Life Sciences — Investor Presentation (December 2021) on 6ix